Form 144 RECURSION PHARMACEUTICAL Filed by: Borgeson Blake
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock [Yahoo! Finance]Yahoo! Finance
- Recursion: Path Forward For REC-994 Remains Despite Mixed Response [Seeking Alpha]Seeking Alpha
- Recursion Stock Down Despite Meeting Goal in Brain Disease Study [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
RXRX
Earnings
- 8/8/24 - Miss
RXRX
Sec Filings
- 9/26/24 - Form 144
- 9/19/24 - Form 4
- 9/19/24 - Form DEFA14A
- RXRX's page on the SEC website